



Clinical trial results:

A phase III, open study in children previously enrolled in study 10PN-PD-DIT-037 (111188) to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate vaccine when administered as a booster dose at either 9-18 or 15-18 months of age in primed children or when administered as a catch-up vaccination (2+1 schedule) in unprimed children during the second year of life.

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2011-002140-27 |
| Trial protocol | Outside EU/EEA |
| Global end of trial date | 19 August 2011 |

Results information

| | |
|--------------------------------|---|
| Result version number | v2 |
| This version publication date | 24 April 2016 |
| First version publication date | 24 May 2015 |
| Version creation reason | • Correction of full data set Data correction due to a system error in EudraCT – Results |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 112909 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01030822 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089904466, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMA-000673-PIP01-09 |

| | |
|--|----|
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 22 March 2012 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|----------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 19 August 2011 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To assess the immune responses following vaccination with a booster dose of the 10Pn-PD-DiT vaccine administered at either 9-12 or 15-18 months of age in children previously vaccinated with the 10Pn-PD-DiT vaccine in study 10PN-PD-DIT-037 (111188) according to a 3-dose primary vaccination at 6, 10 and 14 weeks of age.

Protection of trial subjects:

All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up for one month (minimum 30 days) following administration of the last dose of study vaccines.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 02 April 2010 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | India: 287 |
| Worldwide total number of subjects | 287 |
| EEA total number of subjects | 0 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|--|-----|
| Infants and toddlers (28 days-23 months) | 287 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details: -

Pre-assignment period milestones

| | |
|----------------------------|-----|
| Number of subjects started | 287 |
|----------------------------|-----|

| | |
|------------------------------|-----|
| Number of subjects completed | 282 |
|------------------------------|-----|

Pre-assignment subject non-completion reasons

| | |
|----------------------------|-----------------------|
| Reason: Number of subjects | Consent withdrawal: 2 |
|----------------------------|-----------------------|

| | |
|----------------------------|-------------------------------------|
| Reason: Number of subjects | Other – migrated from study area: 3 |
|----------------------------|-------------------------------------|

Period 1

| | |
|----------------|---------------------------------|
| Period 1 title | Overall period (overall period) |
|----------------|---------------------------------|

| | |
|------------------------------|-----|
| Is this the baseline period? | Yes |
|------------------------------|-----|

| | |
|-------------------|-------------------------|
| Allocation method | Randomised - controlled |
|-------------------|-------------------------|

| | |
|---------------|-------------|
| Blinding used | Not blinded |
|---------------|-------------|

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|-----------|--------|
| Arm title | Pn-Pn9 |
|-----------|--------|

Arm description:

Subjects previously primed with a 3-dose primary vaccination of Synflorix™ vaccine in study 10PN-PD-DIT-037 (111188) received a booster dose at 9-18 months of age.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|------------|
| Investigational medicinal product name | Synflorix™ |
|--|------------|

| | |
|--|--|
| Investigational medicinal product code | |
|--|--|

| | |
|------------|-------------|
| Other name | 10Pn-PD-DiT |
|------------|-------------|

| | |
|----------------------|--------------------------|
| Pharmaceutical forms | Suspension for injection |
|----------------------|--------------------------|

| | |
|--------------------------|-------------------|
| Routes of administration | Intramuscular use |
|--------------------------|-------------------|

Dosage and administration details:

1 booster dose at 9-18 months of age, administered in in the right or left thigh.

| | |
|-----------|---------|
| Arm title | Pn-Pn15 |
|-----------|---------|

Arm description:

Subjects previously primed with a 3-dose primary vaccination of Synflorix™ vaccine in study 10PN-PD-DIT-037 (111188) received a booster dose at 15-18 months of age.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|------------|
| Investigational medicinal product name | Synflorix™ |
|--|------------|

| | |
|--|--|
| Investigational medicinal product code | |
|--|--|

| | |
|------------|-------------|
| Other name | 10Pn-PD-DiT |
|------------|-------------|

| | |
|----------------------|--------------------------|
| Pharmaceutical forms | Suspension for injection |
|----------------------|--------------------------|

| | |
|--------------------------|-------------------|
| Routes of administration | Intramuscular use |
|--------------------------|-------------------|

Dosage and administration details:

1 booster dose at 15-18 months of age, administered in in the right or left thigh.

| | |
|-----------|--------|
| Arm title | Hib-Pn |
|-----------|--------|

Arm description:

unprimed subjects previously vaccinated with Tritanrix™-HepB and Hiberix™ vaccines in the Control Group of study 10PN-PD-DIT-037 (111188) received a catch-up vaccination with the Synflorix™ vaccine (2 primary doses +1booster dose) during their second year of life: 2+1 catch-up vaccination starting at 12-18 months of age with an interval of at least 8 weeks (56-118 days) between primary doses; the booster dose was administered at 18-24 months of age..

| | |
|--|--------------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Synflorix™ |
| Investigational medicinal product code | |
| Other name | 10Pn-PD-DiT |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

1 booster dose at 15-18 months of age, administered in in the right or left thigh.

| | |
|--|--------------------------|
| Investigational medicinal product name | Tritanrix™-HepB |
| Investigational medicinal product code | |
| Other name | DTPw-HBV |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

unprimed subjects previously vaccinated with 3 doses of Tritanrix™-HepB vaccines in the Control Group of study 10PN-PD-DIT-037.

| | |
|--|--------------------------|
| Investigational medicinal product name | Hiberix™ |
| Investigational medicinal product code | |
| Other name | Hib |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

unprimed subjects previously vaccinated with 3 doses of Hiberix™ vaccines in the Control Group of study 10PN-PD-DIT-037.

| Number of subjects in period 1^[1] | Pn-Pn9 | Pn-Pn15 | Hib-Pn |
|---|--------|---------|--------|
| Started | 100 | 95 | 87 |
| Completed | 69 | 71 | 61 |
| Not completed | 31 | 24 | 26 |
| Consent withdrawn by subject | 16 | 13 | 16 |
| Lost to follow-up | 9 | 4 | 7 |
| Moved/migrated from study area | 6 | 7 | 3 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 5 subjects were enrolled but no vaccine was administered.

Baseline characteristics

Reporting groups

| | |
|--|---------|
| Reporting group title | Pn-Pn9 |
| Reporting group description: Subjects previously primed with a 3-dose primary vaccination of Synflorix™ vaccine in study 10PN-PD-DIT-037 (111188) received a booster dose at 9-18 months of age. | |
| Reporting group title | Pn-Pn15 |
| Reporting group description: Subjects previously primed with a 3-dose primary vaccination of Synflorix™ vaccine in study 10PN-PD-DIT-037 (111188) received a booster dose at 15-18 months of age. | |
| Reporting group title | Hib-Pn |
| Reporting group description: unprimed subjects previously vaccinated with Tritanrix™-HepB and Hiberix™ vaccines in the Control Group of study 10PN-PD-DIT-037 (111188) received a catch-up vaccination with the Synflorix™ vaccine (2 primary doses +1booster dose) during their second year of life: 2+1 catch-up vaccination starting at 12-18 months of age with an interval of at least 8 weeks (56-118 days) between primary doses; the booster dose was administered at 18-24 months of age.. | |

| Reporting group values | Pn-Pn9 | Pn-Pn15 | Hib-Pn |
|------------------------------------|--------|---------|--------|
| Number of subjects | 100 | 95 | 87 |
| Age categorical Units: Subjects | | | |

| | | | |
|--|----------------|----------------|----------------|
| Age continuous Units: months arithmetic mean standard deviation | 12.5 ± 2.74 | 15.6 ± 1.27 | 16.1 ± 1.18 |
| Gender categorical Units: Subjects | | | |
| Female | 39 | 50 | 48 |
| Male | 61 | 45 | 39 |

| Reporting group values | Total | | |
|------------------------------------|-------|--|--|
| Number of subjects | 282 | | |
| Age categorical Units: Subjects | | | |

| | | | |
|--|-----|--|--|
| Age continuous Units: months arithmetic mean standard deviation | - | | |
| Gender categorical Units: Subjects | | | |
| Female | 137 | | |
| Male | 145 | | |

End points

End points reporting groups

| | |
|--|---------|
| Reporting group title | Pn-Pn9 |
| Reporting group description: Subjects previously primed with a 3-dose primary vaccination of Synflorix™ vaccine in study 10PN-PD-DIT-037 (111188) received a booster dose at 9-18 months of age. | |
| Reporting group title | Pn-Pn15 |
| Reporting group description: Subjects previously primed with a 3-dose primary vaccination of Synflorix™ vaccine in study 10PN-PD-DIT-037 (111188) received a booster dose at 15-18 months of age. | |
| Reporting group title | Hib-Pn |
| Reporting group description: unprimed subjects previously vaccinated with Tritanrix™-HepB and Hiberix™ vaccines in the Control Group of study 10PN-PD-DIT-037 (111188) received a catch-up vaccination with the Synflorix™ vaccine (2 primary doses +1booster dose) during their second year of life: 2+1 catch-up vaccination starting at 12-18 months of age with an interval of at least 8 weeks (56-118 days) between primary doses; the booster dose was administered at 18-24 months of age.. | |

Primary: Concentrations of antibodies against vaccine pneumococcal serotypes for Pn-Pn9 and Pn-Pn15 Groups

| | |
|--|---|
| End point title | Concentrations of antibodies against vaccine pneumococcal serotypes for Pn-Pn9 and Pn-Pn15 Groups ^{[1][2]} |
| End point description: Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations < 0.05 g/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for subjects for whom data concerning immunogenicity outcome measures were available at the requested time points. Primary results are results one month after booster vaccination (Mth 1). | |
| End point type | Primary |
| End point timeframe: Prior to booster vaccination (PRE), one month after booster vaccination (Month1) and at approximately 24 months of age: at Month15 for the Pn-Pn9 Group and at Month 9 for Pn-Pn15 Group (24 mths of age). | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis was performed on Pn-Pn9 and Pn-Pn15 Groups for the timepoints defined in this endpoint

| End point values | Pn-Pn9 | Pn-Pn15 | | |
|--|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 89 | 71 | | |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |

| | | | | |
|-----------------------------------|------------------------|-----------------------|--|--|
| Anti-1 PRE (N=88;69) | 0.37 (0.29 to 0.48) | 0.31 (0.23 to 0.41) | | |
| Anti-1 Month 1 (N=80;61) | 4.78 (3.87 to 5.91) | 5.98 (4.54 to 7.9) | | |
| Anti-1 24 mths of age (N=59;55) | 0.96 (0.68 to 1.37) | 1.37 (1 to 1.87) | | |
| Anti-4 PRE (N=88;68) | 0.76 (0.58 to 1) | 0.58 (0.44 to 0.75) | | |
| Anti-4 Month 1 (N=81;63) | 7.28 (5.41 to 9.79) | 11.56 (7.96 to 16.79) | | |
| Anti-4 24 mths of age (N=59;55) | 1.24 (0.9 to 1.7) | 2.29 (1.53 to 3.42) | | |
| Anti-5 PRE (N=88;69) | 0.5 (0.4 to 0.63) | 0.38 (0.29 to 0.48) | | |
| Anti-5 Month 1 (N=81;62) | 5.86 (4.69 to 7.32) | 7.2 (5.25 to 9.86) | | |
| Anti-5 24 mths of age (N=59;55) | 1.19 (0.86 to 1.65) | 2.03 (1.43 to 2.86) | | |
| Anti-6B PRE (N=88;71) | 0.65 (0.5 to 0.85) | 0.49 (0.37 to 0.64) | | |
| Anti-6B Month 1 (N=81;64) | 2.82 (2.16 to 3.68) | 2.98 (2.05 to 4.32) | | |
| Anti-6B 24 mths of age (N=59;55) | 0.78 (0.54 to 1.11) | 0.9 (0.61 to 1.32) | | |
| Anti-7F PRE (N=88;70) | 1.12 (0.92 to 1.38) | 0.93 (0.73 to 1.19) | | |
| Anti-7F Month 1 (N=81;63) | 6.3 (4.8 to 8.25) | 7.89 (5.91 to 10.54) | | |
| Anti-7F 24 mths of age (N=59;55) | 1.3 (0.96 to 1.76) | 1.98 (1.43 to 2.75) | | |
| Anti-9V PRE (N=88;71) | 1.2 (0.94 to 1.52) | 0.96 (0.74 to 1.25) | | |
| Anti-9V Month 1 (N=81;64) | 8.03 (6.03 to 10.69) | 9.76 (7.08 to 13.44) | | |
| Anti-9V 24 mths of age (N=58;55) | 1.7 (1.2 to 2.41) | 2.27 (1.64 to 3.14) | | |
| Anti-14 PRE (N=89;70) | 1.76 (1.22 to 2.53) | 1.52 (1.08 to 2.15) | | |
| Anti-14 Month 1 (N=81;64) | 10.18 (7.6 to 13.65) | 11.85 (8.15 to 17.22) | | |
| Anti-14 24 mths of age (N=59;55) | 3.02 (2.09 to 4.37) | 4.11 (2.98 to 5.67) | | |
| Anti-18C PRE (N=89;71) | 2.51 (1.94 to 3.23) | 1.55 (1.19 to 2.03) | | |
| Anti-18C Month 1 (N=81;63) | 33.39 (24.73 to 45.08) | 42.43 (31.48 to 57.2) | | |
| Anti-18C 24 mths of age (N=59;55) | 5.56 (3.84 to 8.05) | 10.04 (6.55 to 15.37) | | |
| Anti-19F PRE (N=89;70) | 1.78 (1.34 to 2.36) | 1.23 (0.97 to 1.57) | | |
| Anti-19F Month 1 (N=81;64) | 13.68 (9.86 to 18.97) | 13.64 (9.42 to 19.76) | | |
| Anti-19F 24 mths of age (N=59;55) | 2.57 (1.81 to 3.65) | 4.15 (2.88 to 5.98) | | |
| Anti-23F PRE (N=88;70) | 0.73 (0.55 to 0.97) | 0.65 (0.48 to 0.89) | | |
| Anti-23F Month 1 (N=81;63) | 5.54 (4.02 to 7.63) | 6.48 (4.69 to 8.96) | | |
| Anti-23F 24 mths of age (N=59;55) | 1.3 (0.88 to 1.91) | 1.38 (0.96 to 1.98) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against vaccine pneumococcal serotypes for Hib-Pn Group.

| | |
|-----------------|--|
| End point title | Concentrations of antibodies against vaccine pneumococcal serotypes for Hib-Pn Group. ^[3] |
|-----------------|--|

End point description:

Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations < 0.05 g/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for subjects for whom data concerning immunogenicity outcome measures were available at the requested time points.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to vaccination (PRE), one month post-Dose 2 (Month 3), prior to (Month 6) and one month after the third (booster) vaccine dose (Month 7) for the Hib-Pn Group

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The analysis was performed on Hib-Pn Group for the timepoints defined in this endpoint

| End point values | Hib-Pn | | | |
|--|----------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 81 | | | |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-1 PRE (N=81) | 0.04 (0.03 to 0.04) | | | |
| Anti-1 Month 3 (N=69) | 2.5 (1.93 to 3.24) | | | |
| Anti-1 Month 6 (N=65) | 1.03 (0.82 to 1.29) | | | |
| Anti-1 Month 7 (N=54) | 3.32 (2.69 to 4.1) | | | |
| Anti-4 PRE (N=80) | 0.04 (0.03 to 0.05) | | | |
| Anti-4 Month 3 (N=71) | 5.89 (4.23 to 8.22) | | | |
| Anti-4 Month 6 (N=65) | 2.23 (1.85 to 2.69) | | | |
| Anti-4 Month 7 (N=54) | 8.22 (5.92 to 11.42) | | | |
| Anti-5 PRE (N=80) | 0.05 (0.04 to 0.06) | | | |

| | | | | |
|-------------------------|------------------------|--|--|--|
| Anti-5 Month 3 (N=71) | 2.81 (2.2 to 3.58) | | | |
| Anti-5 Month 6 (N=65) | 1.39 (1.13 to 1.7) | | | |
| Anti-5 Month 7 (N=54) | 5.32 (4.21 to 6.72) | | | |
| Anti-6B PRE (N=80) | 0.03 (0.03 to 0.04) | | | |
| Anti-6B Month 3 (N=70) | 0.71 (0.53 to 0.95) | | | |
| Anti-6B Month 6 (N=65) | 0.61 (0.47 to 0.78) | | | |
| Anti-6B Month 7 (N=54) | 1.4 (1.04 to 1.88) | | | |
| Anti-7F PRE (N=81) | 0.06 (0.05 to 0.08) | | | |
| Anti-7F Month 3 (N=71) | 4.63 (3.38 to 6.34) | | | |
| Anti-7F Month 6 (N=65) | 2.72 (2.28 to 3.24) | | | |
| Anti-7F Month 7 (N=54) | 7.41 (5.87 to 9.34) | | | |
| Anti-9V PRE (N=80) | 0.04 (0.03 to 0.05) | | | |
| Anti-9V Month 3 (N=71) | 2.09 (1.53 to 2.87) | | | |
| Anti-9V Month 6 (N=65) | 1.74 (1.4 to 2.17) | | | |
| Anti-9V Month 7 (N=54) | 4.88 (3.73 to 6.37) | | | |
| Anti-14 PRE (N=80) | 0.06 (0.05 to 0.08) | | | |
| Anti-14 Month 3 (N=71) | 5.01 (3.75 to 6.69) | | | |
| Anti-14 Month 6 (N=65) | 2.84 (2.25 to 3.57) | | | |
| Anti-14 Month 7 (N=54) | 7.59 (5.87 to 9.8) | | | |
| Anti-18C PRE (N=80) | 0.04 (0.03 to 0.05) | | | |
| Anti-18C Month 3 (N=70) | 29.1 (19.86 to 42.64) | | | |
| Anti-18C Month 6 (N=65) | 12.44 (9.16 to 16.91) | | | |
| Anti-18C Month 7 (N=54) | 75.19 (57.69 to 98.01) | | | |
| Anti-19F PRE (N=80) | 0.07 (0.05 to 0.1) | | | |
| Anti-19F Month 3 (N=71) | 16.39 (11.15 to 24.1) | | | |
| Anti-19F Month 6 (N=65) | 7.74 (5.85 to 10.24) | | | |
| Anti-19F Month 7 (N=54) | 30.71 (23.76 to 39.68) | | | |
| Anti-23F PRE (N=80) | 0.04 (0.03 to 0.05) | | | |
| Anti-23F Month 3 (N=71) | 1.13 (0.82 to 1.57) | | | |
| Anti-23F Month 6 (N=65) | 0.85 (0.67 to 1.09) | | | |
| Anti-23F Month 7 (N=54) | 2.15 (1.69 to 2.75) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against vaccine pneumococcal serotypes (Persistence)

| | |
|-----------------|---|
| End point title | Concentrations of antibodies against vaccine pneumococcal serotypes (Persistence) |
|-----------------|---|

End point description:

Antibodies assessed for this outcome measure were those against the vaccine pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (ANTI-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter ($\mu\text{g/mL}$). The seropositivity cut-off of the assay was an antibody concentration $\geq 0.05 \mu\text{g/mL}$. Antibody concentrations $< 0.05 \text{ g/mL}$ were given an arbitrary value of half the cut-off for the purpose of GMC calculation. The analysis was performed on the according-to-protocol cohort for persistence, e. a., evaluable subjects for subjects for whom assay results for antibodies against at least one pneumococcal serotype were available before the administration of the booster dose of the 10Pn-PD-DiT vaccine.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to booster vaccination (PRE) for the Pn-Pn9 Group and for Pn-Pn15 Group and prior to catch-up vaccination (PRE) for the Hib-Pn Group

| End point values | Pn-Pn9 | Pn-Pn15 | Hib-Pn | |
|--|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 89 | 90 | 84 | |
| Units: $\mu\text{g/mL}$ | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-1 (N=88;87;84) | 0.37 (0.29 to 0.48) | 0.3 (0.24 to 0.39) | 0.04 (0.03 to 0.04) | |
| Anti-4 (N=88;85;83) | 0.76 (0.58 to 1) | 0.57 (0.45 to 0.72) | 0.04 (0.03 to 0.05) | |
| Anti-5 (N=88;87;83) | 0.5 (0.4 to 0.63) | 0.38 (0.31 to 0.47) | 0.05 (0.04 to 0.06) | |
| Anti-6B (N=88;90;83) | 0.65 (0.5 to 0.85) | 0.51 (0.4 to 0.65) | 0.03 (0.03 to 0.04) | |
| Anti-7F (N=88;89;84) | 1.12 (0.92 to 1.38) | 0.98 (0.79 to 1.23) | 0.06 (0.04 to 0.08) | |
| Anti-9V (N=88;90;83) | 1.2 (0.94 to 1.52) | 0.98 (0.78 to 1.23) | 0.04 (0.03 to 0.05) | |
| Anti-14 (N=89;89;83) | 1.76 (1.22 to 2.53) | 1.37 (1 to 1.87) | 0.06 (0.05 to 0.08) | |
| Anti-18C (N=89;90;83) | 2.51 (1.94 to 3.23) | 1.61 (1.26 to 2.05) | 0.04 (0.03 to 0.05) | |
| Anti-19F (N=89;88;83) | 1.78 (1.34 to 2.36) | 1.36 (1.1 to 1.68) | 0.07 (0.05 to 0.09) | |
| Anti-23F (N=88;88;83) | 0.73 (0.55 to 0.97) | 0.64 (0.49 to 0.85) | 0.04 (0.03 to 0.05) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F(Persistence).

| | |
|-----------------|---|
| End point title | Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F(Persistence). |
|-----------------|---|

End point description:

OPA titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8 . Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation. The analysis was performed on the according-to-protocol cohort for persistence, e. a., evaluable subjects for subjects for whom assay results for antibodies against at least one pneumococcal serotype were available before the administration of the booster dose of the 10Pn-PD-DiT vaccine.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to booster vaccination (PRE) for the Pn-Pn9 Group and for Pn-Pn15 Group and prior to catch-up vaccination (PRE) for the Hib-Pn Group

| End point values | Pn-Pn9 | Pn-Pn15 | Hib-Pn | |
|--|------------------------|---------------------------|--------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 87 | 84 | 78 | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Opsono-1 (N=87;84;77) | 16.5 (11.2 to 24.3) | 15.6 (10.5 to 23) | 4.4 (3.9 to 5) | |
| Opsono-4 (N=85;81;67) | 70.3 (43.9 to 112.5) | 102.8 (66.4 to 159.1) | 6.2 (4.2 to 9.3) | |
| Opsono-5 (N=87;81;78) | 11.9 (8.9 to 15.9) | 10.4 (7.8 to 13.7) | 4.2 (3.8 to 4.7) | |
| Opsono-6B (N=87;82;71) | 50.2 (30.7 to 82.1) | 62 (36.5 to 105.5) | 5.3 (3.9 to 7) | |
| Opsono-7F (N=87;84;65) | 1162.5 (910 to 1485) | 1551.1 (1269.4 to 1895.3) | 1186.4 (588.8 to 2390.7) | |
| Opsono-9V (N=83;82;60) | 430.4 (310.7 to 596.1) | 617.6 (477.6 to 798.6) | 192.6 (93.6 to 396.5) | |
| Opsono-14 (N=85;79;69) | 206.4 (134.2 to 317.5) | 166.3 (105.7 to 261.6) | 13.5 (7.8 to 23.5) | |
| Opsono-18C (N=85;81;74) | 30.4 (20.7 to 44.6) | 23 (15.6 to 34) | 4.8 (3.8 to 6) | |
| Opsono-19F (N=86;82;76) | 43 (29.9 to 61.7) | 42.4 (29.5 to 60.8) | 4.2 (3.9 to 4.6) | |
| Opsono-23F (N=86;80;72) | 157 (83.2 to 296.3) | 531.1 (280.3 to 1006.4) | 41.9 (18.8 to 93.2) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F for Pn-Pn9 and Pn-Pn15 Groups

| | |
|-----------------|--|
| End point title | Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F for Pn-Pn9 and Pn-Pn15 Groups ^[4] |
|-----------------|--|

End point description:

OPA titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8 . Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for subjects for whom data concerning immunogenicity outcome measures were available at the requested time points.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to booster vaccination (PRE), one month after booster vaccination (Month1) and at approximately 24 months of age: at Month15 for the Pn-Pn9 Group and at Month 9 for Pn-Pn15 Group (24 mths of age).

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The analysis was performed on Pn-Pn9 and Pn-Pn15 Groups for the timepoints defined in this endpoint

| End point values | Pn-Pn9 | Pn-Pn15 | | |
|--|--------------------------|---------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 87 | 65 | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Opsono-1 PRE (N=87;65) | 16.5 (11.2 to 24.3) | 14.3 (9.3 to 22.1) | | |
| Opsono-1 Month 1 (N=79;58) | 1138.3 (828.6 to 1563.7) | 2096.7 (1464.8 to 3001.1) | | |
| Opsono-1 24 mths of age (N=57;54) | 69.6 (40.1 to 121) | 173.8 (105.5 to 286.5) | | |
| Opsono-4 PRE (N=85;63) | 70.3 (43.9 to 112.5) | 101.6 (62.6 to 164.9) | | |
| Opsono-4 Month 1 (N=79;58) | 3368.8 (2618 to 4334.9) | 7202.1 (5336.1 to 9720.6) | | |
| Opsono-4 24 mths of age (N=57;54) | 557.4 (284 to 1093.9) | 2525.6 (1474.5 to 4325.9) | | |
| Opsono-5 PRE (N=87;62) | 11.9 (8.9 to 15.9) | 9.7 (7.2 to 13.1) | | |
| Opsono-5 Month 1 (N=79;58) | 452.7 (353 to 580.6) | 834.6 (610.9 to 1140.2) | | |

| | | | | |
|-------------------------------------|----------------------------|-----------------------------|--|--|
| Opsono-5 24 mths of age (N=56;55) | 45.7 (29.6 to 70.7) | 90.6 (54.8 to 149.8) | | |
| Opsono-6B PRE (N=87;63) | 50.2 (30.7 to 82.1) | 60 (32.9 to 109.3) | | |
| Opsono-6B Month 1 (N=79;57) | 1556.6 (1090 to 2223) | 1781.2 (1042.5 to 3043.6) | | |
| Opsono-6B 24 mths of age (N=51;52) | 241.4 (127.7 to 456.4) | 287.5 (149 to 555) | | |
| Opsono-7F PRE (N=87;65) | 1162.5 (910 to 1485) | 1539.1 (1262.9 to 1875.6) | | |
| Opsono-7F Month 1 (N=79;57) | 7814.8 (5984.8 to 10204.3) | 11064.4 (8182.9 to 14960.5) | | |
| Opsono-7F 24 mths of age (N=55;52) | 2891.2 (1954.4 to 4276.9) | 5371.9 (3712.4 to 7773.4) | | |
| Opsono-9V PRE (N=83;63) | 430.4 (310.7 to 596.1) | 704.9 (533.7 to 931.1) | | |
| Opsono-9V Month 1 (N=79;58) | 4440 (3305.4 to 5964.2) | 7870.3 (5634.4 to 10993.4) | | |
| Opsono-9V 24 mths of age (N=49;52) | 1926.1 (1316.6 to 2817.9) | 3504.5 (2501 to 4910.6) | | |
| Opsono-14 PRE (N=85;62) | 206.4 (134.2 to 317.5) | 184 (109.8 to 308.2) | | |
| Opsono-14 Month 1 (N=79;57) | 2057.1 (1569.6 to 2696.1) | 4407.5 (3193.2 to 6083.5) | | |
| Opsono-14 24 mths of age (N=56;53) | 668.5 (403.1 to 1108.6) | 1641.2 (944.2 to 2852.9) | | |
| Opsono-18C PRE (N=85;62) | 30.4 (20.7 to 44.6) | 22.2 (14.1 to 35) | | |
| Opsono-18C Month 1 (N=79;58) | 1889.7 (1429.4 to 2498.1) | 3643.2 (2572.2 to 5160.2) | | |
| Opsono-18C 24 mths of age (N=52;53) | 233.6 (142.2 to 383.8) | 1155 (662 to 2015) | | |
| Opsono-19F PRE (N=86;63) | 43 (29.9 to 61.7) | 34.7 (23.4 to 51.6) | | |
| Opsono-19F Month 1 (N=78;58) | 1672.9 (1096.3 to 2552.7) | 2404.4 (1583.1 to 3651.6) | | |
| Opsono-19F 24 mths of age (N=51;53) | 107.3 (61.4 to 187.6) | 357.9 (218.9 to 585) | | |
| Opsono-23F PRE (N=86;61) | 157 (83.2 to 296.3) | 498.2 (231.4 to 1072.9) | | |
| Opsono-23F Month 1 (N=79;58) | 3812.3 (2630.8 to 5524.5) | 5937.2 (3587.6 to 9825.5) | | |
| Opsono-23F 24 mths of age (N=54;55) | 1994.1 (959.7 to 4143.4) | 3018.5 (1389 to 6559.6) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F for Hib-Pn Group

| | |
|-----------------|---|
| End point title | Opsonophagocytic activity (OPA) titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F for Hib-Pn Group ^[5] |
|-----------------|---|

End point description:

OPA titers against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Opsono-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8 . Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for subjects for whom data concerning immunogenicity outcome measures were available at the requested time points.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to vaccination (PRE), one month post-Dose 2 (Month 3), prior to (Month 6) and one month after the third (booster) vaccine dose (Month 7) for the Hib-Pn Group

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis was performed on Hib-Pn Group for the timepoints defined in this endpoint

| End point values | Hib-Pn | | | |
|--|---------------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 75 | | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Opsono-1 PRE (N=74) | 4.3 (3.9 to 4.8) | | | |
| Opsono-1 Month 3 (N=68) | 76.1 (49 to 118.2) | | | |
| Opsono-1 Month 6 (N=64) | 18.1 (11.5 to 28.4) | | | |
| Opsono-1 Month 7 (N=54) | 309.8 (203 to 472.9) | | | |
| Opsono-4 PRE (N=64) | 5.8 (4 to 8.6) | | | |
| Opsono-4 Month 3 (N=66) | 2256.3 (1840 to 2766.8) | | | |
| Opsono-4 Month 6 (N=63) | 959.7 (727.2 to 1266.6) | | | |
| Opsono-4 Month 7 (N=54) | 2946.2 (2097.9 to 4137.4) | | | |
| Opsono-5 PRE (N=75) | 4.2 (3.8 to 4.7) | | | |
| Opsono-5 Month 3 (N=64) | 76.3 (53.3 to 109.3) | | | |
| Opsono-5 Month 6 (N=63) | 24.6 (17 to 35.6) | | | |
| Opsono-5 Month 7 (N=54) | 212 (148.9 to 301.7) | | | |
| Opsono-6B PRE (N=68) | 5.3 (3.9 to 7.2) | | | |
| Opsono-6B Month 3 (N=63) | 348.2 (165.7 to 731.6) | | | |
| Opsono-6B Month 6 (N=61) | 201.5 (98.2 to 413.5) | | | |
| Opsono-6B Month 7 (N=53) | 740.5 (419.6 to 1306.8) | | | |
| Opsono-7F PRE (N=63) | 1106.8 (540.7 to 2265.9) | | | |

| | | | | |
|---------------------------|----------------------------|--|--|--|
| Opsono-7F Month 3 (N=67) | 7462.5 (5653.9 to 9849.6) | | | |
| Opsono-7F Month 6 (N=63) | 6295.9 (4545 to 8721.4) | | | |
| Opsono-7F Month 7 (N=54) | 10104 (7377.8 to 13837.4) | | | |
| Opsono-9V PRE (N=58) | 205.9 (98.7 to 429.4) | | | |
| Opsono-9V Month 3 (N=61) | 5792.5 (4586.3 to 7315.9) | | | |
| Opsono-9V Month 6 (N=62) | 3463.4 (2716.3 to 4416.1) | | | |
| Opsono-9V Month 7 (N=53) | 7000 (5265.1 to 9306.6) | | | |
| Opsono-14 PRE (N=67) | 12.4 (7.1 to 21.6) | | | |
| Opsono-14 Month 3 (N=65) | 2359.8 (1576.1 to 3533.2) | | | |
| Opsono-14 Month 6 (N=63) | 1293.6 (886.8 to 1887.2) | | | |
| Opsono-14 Month 7 (N=54) | 3709.4 (2463.5 to 5585.2) | | | |
| Opsono-18C PRE (N=71) | 4.8 (3.8 to 6.1) | | | |
| Opsono-18C Month 3 (N=66) | 2487.5 (1541.2 to 4014.8) | | | |
| Opsono-18C Month 6 (N=62) | 2546.4 (1755 to 3694.7) | | | |
| Opsono-18C Month 7 (N=54) | 8814.6 (6810.9 to 11407.7) | | | |
| Opsono-19F PRE (N=73) | 4.2 (3.9 to 4.6) | | | |
| Opsono-19F Month 3 (N=65) | 1768.6 (1120.3 to 2792) | | | |
| Opsono-19F Month 6 (N=62) | 753.8 (497.3 to 1142.5) | | | |
| Opsono-19F Month 7 (N=51) | 3808.8 (2689.5 to 5393.9) | | | |
| Opsono-23F PRE (N=69) | 38.7 (17.1 to 87.5) | | | |
| Opsono-23F Month 3 (N=67) | 3378.1 (2014.8 to 5664) | | | |
| Opsono-23F Month 6 (N=62) | 1868.2 (956.9 to 3647.5) | | | |
| Opsono-23F Month 7 (N=53) | 4357.3 (2246.9 to 8449.8) | | | |

Statistical analyses

Secondary: Concentrations of antibodies against cross-reactive pneumococcal serotypes 6A and 19A (Persistence)

| | |
|-----------------|---|
| End point title | Concentrations of antibodies against cross-reactive pneumococcal serotypes 6A and 19A (Persistence) |
|-----------------|---|

End point description:

Antibodies assessed for this outcome measure were those against cross-reactive pneumococcal serotypes 6A and 19A (ANTI-6A and -19A). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations < 0.05 g/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation. The analysis was performed on the according-to-protocol cohort for persistence, e. a., evaluable subjects for subjects for whom assay results for antibodies against at least one pneumococcal serotype were available before the administration of the booster dose of the 10Pn-PD-DiT vaccine.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to booster vaccination (PRE) for the Pn-Pn9 Group and for Pn-Pn15 Group and prior to catch-up vaccination (PRE) for the Hib-Pn Group

| End point values | Pn-Pn9 | Pn-Pn15 | Hib-Pn | |
|--|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 89 | 89 | 84 | |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-6A (N=89;87;83) | 0.19 (0.14 to 0.26) | 0.22 (0.16 to 0.29) | 0.03 (0.03 to 0.04) | |
| Anti-19A (N=88;89;84) | 0.31 (0.21 to 0.45) | 0.33 (0.25 to 0.45) | 0.06 (0.04 to 0.08) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against cross-reactive pneumococcal serotypes 6A and 19A for Pn-Pn9 and Pn-Pn15 Groups.

| | |
|-----------------|---|
| End point title | Concentrations of antibodies against cross-reactive pneumococcal serotypes 6A and 19A for Pn-Pn9 and Pn-Pn15 Groups. ^[6] |
|-----------------|---|

End point description:

Antibodies assessed for this outcome measure were those against the cross-reactive pneumococcal serotypes 6A and 19A (ANTI-6A and -19A). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations < 0.05 g/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for subjects for whom data concerning immunogenicity outcome measures were available at the requested time points.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to booster vaccination (PRE), one month after booster vaccination (Month1) and at approximately 24 months of age: at Month15 for the Pn-Pn9 Group and at Month 9 for Pn-Pn15 Group (24 mths of age).

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis was performed on Pn-Pn9 and Pn-Pn15 Groups for the timepoints defined in this endpoint

| End point values | Pn-Pn9 | Pn-Pn15 | | |
|--|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 89 | 70 | | |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-6A PRE (N=89;70) | 0.19 (0.14 to 0.26) | 0.19 (0.14 to 0.27) | | |
| Anti-6A Month 1 (N=81;62) | 0.82 (0.59 to 1.14) | 0.95 (0.63 to 1.44) | | |
| Anti-6A 24 mths of age (N=59;55) | 0.32 (0.22 to 0.48) | 0.36 (0.22 to 0.59) | | |
| Anti-19A PRE (N=88;70) | 0.31 (0.21 to 0.45) | 0.3 (0.22 to 0.41) | | |
| Anti-19A Month 1 (N=81;64) | 2.54 (1.61 to 4.03) | 2.87 (1.78 to 4.61) | | |
| Anti-19A 24 mths of age (N=59;55) | 0.71 (0.45 to 1.14) | 1.33 (0.85 to 2.08) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against cross-reactive pneumococcal serotypes 6A and 19A for Hib-Pn Group.

| | |
|-----------------|--|
| End point title | Concentrations of antibodies against cross-reactive pneumococcal serotypes 6A and 19A for Hib-Pn Group. ^[7] |
|-----------------|--|

End point description:

Antibodies assessed for this outcome measure were those against cross-reactive pneumococcal serotypes 6A and 19A (ANTI-6A and -19A). Antibody concentrations were measured by 22F enzyme-linked immunosorbent assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The seropositivity cut-off of the assay was an antibody concentration ≥ 0.05 µg/mL. Antibody concentrations < 0.05 g/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for whom data concerning immunogenicity outcome measures were available at the requested time points.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to vaccination (PRE), one month post-Dose 2 (Month 3), prior to (Month 6) and one month after the third (booster) vaccine dose (Month 7) for the Hib-Pn Group

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis was performed on Hib-Pn Group for the timepoints defined in this endpoint

| End point values | Hib-Pn | | | |
|--|----------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 81 | | | |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-6A PRE (N=80) | 0.03 (0.03 to 0.04) | | | |
| Anti-6A Month 3 (N=70) | 0.35 (0.25 to 0.5) | | | |
| Anti-6A Month 6 (N=65) | 0.33 (0.24 to 0.45) | | | |
| Anti-6A Month 7 (N=54) | 0.76 (0.53 to 1.09) | | | |
| Anti-19A PRE (N=81) | 0.06 (0.04 to 0.08) | | | |
| Anti-19A Month 3 (N=71) | 2.49 (1.77 to 3.51) | | | |
| Anti-19A Month 6 (N=65) | 1.94 (1.44 to 2.61) | | | |
| Anti-19A Month 7 (N=54) | 7.91 (5.62 to 11.13) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against cross-reactive pneumococcal serotypes 6A and 19A (Persistence).

| | |
|-----------------|--|
| End point title | Opsonophagocytic activity (OPA) titers against cross-reactive pneumococcal serotypes 6A and 19A (Persistence). |
|-----------------|--|

End point description:

OPA titers against cross-reactive pneumococcal serotypes 6A and 19A (Opsono-6A and -19A) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8 . Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation. The analysis was performed on the according-to-protocol cohort for persistence, e. a., evaluable subjects for subjects for whom assay results for antibodies against at least one pneumococcal serotype were available before the administration of the booster dose of the 10Pn-PD-DiT vaccine.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to booster vaccination (PRE) for the Pn-Pn9 Group and for Pn-Pn15 Group and prior to catch-up vaccination (PRE) for the Hib-Pn Group

| End point values | Pn-Pn9 | Pn-Pn15 | Hib-Pn | |
|--|---------------------|---------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 86 | 82 | 78 | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Opsono-6A (N=86;82;72) | 21.1 (13.2 to 33.6) | 30.1 (18.4 to 49.3) | 10.3 (6.3 to 17) | |

| | | | | |
|-------------------------|-------------------|------------------|----------------|--|
| Opsono-19A (N=86;82;78) | 9.7 (6.8 to 13.7) | 7.4 (5.7 to 9.7) | 4.8 (4 to 5.7) | |
|-------------------------|-------------------|------------------|----------------|--|

Statistical analyses

No statistical analyses for this end point

Secondary: Opsonophagocytic activity (OPA) titers against cross-reactive pneumococcal serotypes 6A and 19A for Pn-Pn9 and Pn-Pn15 Groups

| | |
|-----------------|--|
| End point title | Opsonophagocytic activity (OPA) titers against cross-reactive pneumococcal serotypes 6A and 19A for Pn-Pn9 and Pn-Pn15 Groups ^[8] |
|-----------------|--|

End point description:

OPA titers against cross-reactive pneumococcal serotypes 6A and 19A (Opsono-6A and -19A) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8 . Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for subjects for whom data concerning immunogenicity outcome measures were available at the requested time points.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to booster vaccination (PRE), one month after booster vaccination (Month1) and at approximately 24 months of age: at Month15 for the Pn-Pn9 Group and at Month 9 for Pn-Pn15 Group (24 mths of age).

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The analysis was performed on Pn-Pn9 and Pn-Pn15 Groups for the timepoints defined in this endpoint

| End point values | Pn-Pn9 | Pn-Pn15 | | |
|--|-----------------------|------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 86 | 63 | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Opsono-6A PRE (N=86;63) | 21.1 (13.2 to 33.6) | 27.1 (15.7 to 47) | | |
| Opsono-6A Month 1 (N=79;57) | 168.7 (96.3 to 295.5) | 262.5 (135.4 to 509) | | |
| Opsono-6A 24 mths of age (N=54;53) | 62.2 (33.7 to 114.8) | 96.6 (45.4 to 205.6) | | |
| Opsono-19A PRE (N=86;63) | 9.7 (6.8 to 13.7) | 7 (5.3 to 9.3) | | |
| Opsono-19A Month 1 (N=78;57) | 161.6 (93.7 to 278.5) | 385.6 (223.4 to 665.5) | | |
| Opsono-19A 24 mths of age (N=53;51) | 17.8 (9.8 to 32.1) | 60 (33 to 109.2) | | |

Statistical analyses

Secondary: Opsonophagocytic activity (OPA) titers against cross-reactive pneumococcal serotypes 6A and 19A for Hib-Pn Group

| | |
|-----------------|---|
| End point title | Opsonophagocytic activity (OPA) titers against cross-reactive pneumococcal serotypes 6A and 19A for Hib-Pn Group ^[9] |
|-----------------|---|

End point description:

OPA titers against cross-reactive pneumococcal serotypes 6A and 19A (Opsono-6A and -19A) were calculated, expressed as geometric mean titers (GMTs) and tabulated. The seropositivity cut-off for the assay was ≥ 8 . Antibody titers < 8 were given an arbitrary value of half the cut-off for the purpose of GMT calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for subjects for whom data concerning immunogenicity outcome measures were available at the requested time points.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to vaccination (PRE), one month post-Dose 2 (Month 3), prior to (Month 6) and one month after the third (booster) vaccine dose (Month 7) for the Hib-Pn Group

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis was performed on Hib-Pn Group for the timepoints defined in this endpoint

| End point values | Hib-Pn | | | |
|--|-------------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 75 | | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Opsono-6A PRE (N=69) | 10.2 (6.1 to 17.1) | | | |
| Opsono-6A Month 3 (N=65) | 324.9 (176.1 to 599.5) | | | |
| Opsono-6A Month 6 (N=63) | 329 (181 to 598.2) | | | |
| Opsono-6A Month 7 (N=52) | 616.2 (369.2 to 1028.5) | | | |
| Opsono-19A PRE (N=75) | 4.8 (4 to 5.8) | | | |
| Opsono-19A Month 3 (N=64) | 506.6 (305.5 to 840.1) | | | |
| Opsono-19A Month 6 (N=61) | 402.1 (248.9 to 649.5) | | | |
| Opsono-19A Month 7 (N=54) | 1770.9 (1190.6 to 2634) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against protein D (Anti-PD) (Persistence)

| | |
|-----------------|--|
| End point title | Concentrations of antibodies against protein D (Anti-PD) (Persistence) |
|-----------------|--|

End point description:

Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were

calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL. Antibody concentrations < 100 EL.U/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation. The analysis was performed on the according-to-protocol cohort for persistence, e. a., evaluable subjects for subjects for whom assay results for antibodies against at least one pneumococcal serotype were available before the administration of the booster dose of the 10Pn-PD-DiT vaccine.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to booster vaccination (PRE) for the Pn-Pn9 Group and for Pn-Pn15 Group and prior to catch-up vaccination (PRE) for the Hib-Pn Group.

| End point values | Pn-Pn9 | Pn-Pn15 | Hib-Pn | |
|--|----------------------|------------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 89 | 90 | 82 | |
| Units: EL.U/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-PD | 776.3 (629 to 958.2) | 618.6 (488.2 to 783.9) | 71.6 (62.3 to 82.2) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against protein D (Anti-PD) for Pn-Pn9 and Pn-Pn15 Groups.

| | |
|-----------------|---|
| End point title | Concentrations of antibodies against protein D (Anti-PD) for Pn-Pn9 and Pn-Pn15 Groups. ^[10] |
|-----------------|---|

End point description:

Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL. Antibody concentrations < 100 EL.U/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for subjects for whom data concerning immunogenicity outcome measures were available at the requested time points.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to booster vaccination (PRE), one month after booster vaccination (Month1) and at approximately 24 months of age: at Month15 for the Pn-Pn9 Group and at Month 9 for Pn-Pn15 Group (24 mths of age).

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis was performed on Pn-Pn9 and Pn-Pn15 Groups for the timepoints defined in this endpoint

| End point values | Pn-Pn9 | Pn-Pn15 | | |
|--|-------------------------|-------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 89 | 71 | | |
| Units: EL.U/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-PD PRE (N=89;71) | 776.3 (629 to 958.2) | 654.7 (497.9 to 860.9) | | |
| Anti-PD Month 1 (N=81;61) | 3704.2 (2825.6 to 4856) | 5297.6 (3934 to 7133.8) | | |
| Anti-PD 24 mths of age (N=59;54) | 1337.3 (953.8 to 1875) | 2191.9 (1582.5 to 3036) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Concentrations of antibodies against protein D (Anti-PD) for Hib-Pn Group.

| | |
|-----------------|--|
| End point title | Concentrations of antibodies against protein D (Anti-PD) for Hib-Pn Group. ^[11] |
|-----------------|--|

End point description:

Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL. Antibody concentrations < 100 EL.U/mL were given an arbitrary value of half the cut-off for the purpose of GMC calculation. The analysis was performed on the according-to-protocol cohort for immunogenicity, e. a., evaluable subjects for subjects for whom data concerning immunogenicity outcome measures were available at the requested time points.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Prior to vaccination (PRE), one month post-Dose 2 (Month 3), prior to (Month 6) and one month after the third (booster) vaccine dose (Month 7) for the Hib-Pn Group

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis was performed on Hib-Pn Group for the timepoints defined in this endpoint

| End point values | Hib-Pn | | | |
|--|------------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 79 | | | |
| Units: EL.U/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-PD PRE (N=79) | 72.5 (62.9 to 83.7) | | | |
| Anti-PD Month 3 (N=70) | 527.7 (397.4 to 700.9) | | | |
| Anti-PD Month 6 (N=65) | 443.2 (333.1 to 589.6) | | | |

| | | | | |
|------------------------|---------------------------|--|--|--|
| Anti-PD Month 7 (N=54) | 1727.2 (1306.6 to 2283.3) | | | |
|------------------------|---------------------------|--|--|--|

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any and Grade 3 solicited local symptoms

| | |
|---|--|
| End point title | Number of subjects with any and Grade 3 solicited local symptoms |
| End point description: Solicited local symptoms assessed include pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/spontaneously painful. Grade 3 swelling/redness was defined as swelling/redness larger than (>) 30 millimeters (mm). "Any" is defined as incidence of the specified symptom regardless of intensity. | |
| End point type | Secondary |
| End point timeframe: Within the 4-day follow-up period (Days 0-3) after the booster dose for Pn-Pn9 and Pn-Pn15 Groups and across doses for Hib-Pn Group. | |

| End point values | Pn-Pn9 | Pn-Pn15 | Hib-Pn | |
|-----------------------------|-----------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 93 | 85 | 82 | |
| Units: Subjects | | | | |
| Any Pain | 31 | 25 | 26 | |
| Grade 3 Pain | 2 | 4 | 5 | |
| Any Redness | 16 | 12 | 11 | |
| Grade 3 Redness | 2 | 0 | 1 | |
| Any Swelling | 14 | 14 | 16 | |
| Grade 3 Swelling | 4 | 1 | 2 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number/percentage of subjects with any, grade 3 and related solicited general symptoms

| | |
|---|--|
| End point title | Number/percentage of subjects with any, grade 3 and related solicited general symptoms |
| End point description: Assessed solicited general symptoms were Drowsiness, Irritability/Fussiness (Irr./Fuss.), Loss of appetite (Loss Appet.) and Fever (rectal temperature higher than [\geq] 38.0 degrees Celsius [$^{\circ}$ C]),. Any = Occurrence of the specified solicited general symptom, regardless of intensity or relationship to vaccination. Related = Occurrence of the specified symptom assessed by the investigators as causally related to vaccination. Grade 3 Drowsiness = Drowsiness that prevented normal everyday activities. Grade 3 Irr./Fuss. = Crying that could not be comforted/prevented normal everyday activities. Grade 3 | |

Loss of appetite = Subject did not eat at all. Grade 3 Fever = Rectal temperature higher than (>) 40.0°C.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within the 4-day follow-up period(Days 0-3) after the booster dose for Pn-Pn9 and Pn-Pn15 Groups and across doses for Hib-Pn Group.

| End point values | Pn-Pn9 | Pn-Pn15 | Hib-Pn | |
|-----------------------------|-----------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 92 | 85 | 82 | |
| Units: Subjects | | | | |
| Any Drowsiness | 5 | 4 | 5 | |
| Grade 3 Drowsiness | 0 | 0 | 2 | |
| Related Drowsiness | 4 | 4 | 3 | |
| Any Fever | 20 | 13 | 22 | |
| Grade 3 Fever | 0 | 1 | 0 | |
| Related Fever | 19 | 13 | 21 | |
| Any Irr./Fuss | 19 | 9 | 12 | |
| Grade 3 Irr./Fuss. | 1 | 1 | 1 | |
| Related Irr./Fuss. | 15 | 9 | 9 | |
| Any Loss Appet. | 14 | 9 | 10 | |
| Grade 3 Loss Appet. | 0 | 2 | 0 | |
| Related Loss Appet. | 9 | 8 | 9 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with unsolicited adverse events (AEs)

| | |
|-----------------|--|
| End point title | Number of subjects with unsolicited adverse events (AEs) |
|-----------------|--|

End point description:

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 31-day follow-up period (Days 0-30) after vaccination

| End point values | Pn-Pn9 | Pn-Pn15 | Hib-Pn | |
|-----------------------------|-----------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 100 | 95 | 87 | |
| Units: Subjects | | | | |
| Any AE | 7 | 1 | 5 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with serious adverse events (SAEs)

| | |
|--|---|
| End point title | Number of subjects with serious adverse events (SAEs) |
| End point description: SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity. | |
| End point type | Secondary |
| End point timeframe: During the entire study period e.g. after the first vaccination up to study end | |

| End point values | Pn-Pn9 | Pn-Pn15 | Hib-Pn | |
|-----------------------------|-----------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 100 | 95 | 87 | |
| Units: Subjects | | | | |
| Any SAE | 2 | 0 | 1 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited local and general AEs: during the 4 days post vaccination; Unsolicited AEs: during the 31 days post vaccination after booster dose in the Pn-Pn9 and Pn-Pn15 Groups and across doses in the Hib-Pn Group; SAEs: during the whole study period.

Adverse event reporting additional description:

The occurrence of reported AEs (all/related) was not available and is encoded as equal to the number of subjects affected.

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 14.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--------|
| Reporting group title | Pn-Pn9 |
|-----------------------|--------|

Reporting group description: -

| | |
|-----------------------|--------|
| Reporting group title | Hib-Pn |
|-----------------------|--------|

Reporting group description:

unprimed subjects previously vaccinated with DTPw-HBV and Hib vaccines in the control group of study 10PN-PD-DIT-037 (111188) and receiving a catch-up vaccination with the 10Pn-PD-DiT vaccine (2+1 schedule) during the second year of life.

| | |
|-----------------------|----------|
| Reporting group title | Pn-Pn-15 |
|-----------------------|----------|

Reporting group description: -

| Serious adverse events | Pn-Pn9 | Hib-Pn | Pn-Pn-15 |
|---|-----------------|----------------|----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 100 (2.00%) | 1 / 87 (1.15%) | 0 / 95 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Febrile convulsion | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 87 (1.15%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Skin infection | | | |
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 87 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |

| | | | |
|---|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 100 (1.00%) | 0 / 87 (0.00%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 100 (0.00%) | 1 / 87 (1.15%) | 0 / 95 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Pn-Pn9 | Hib-Pn | Pn-Pn-15 |
|---|-------------------|------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 31 / 100 (31.00%) | 26 / 87 (29.89%) | 25 / 95 (26.32%) |
| General disorders and administration site conditions | | | |
| Pain | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[1] | 31 / 93 (33.33%) | 26 / 82 (31.71%) | 25 / 85 (29.41%) |
| occurrences (all) | 31 | 26 | 25 |
| Redness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[2] | 16 / 93 (17.20%) | 11 / 82 (13.41%) | 12 / 85 (14.12%) |
| occurrences (all) | 16 | 11 | 12 |
| Swelling | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[3] | 14 / 93 (15.05%) | 16 / 82 (19.51%) | 14 / 85 (16.47%) |
| occurrences (all) | 14 | 16 | 14 |
| Drowsiness | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[4] | 5 / 92 (5.43%) | 5 / 82 (6.10%) | 4 / 85 (4.71%) |
| occurrences (all) | 5 | 5 | 4 |
| Fever (≥38°C) | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[5] | 20 / 92 (21.74%) | 22 / 82 (26.83%) | 13 / 85 (15.29%) |
| occurrences (all) | 20 | 22 | 13 |

| | | | |
|--|------------------|------------------|-----------------|
| Irritability | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[6] | 19 / 92 (20.65%) | 12 / 82 (14.63%) | 9 / 85 (10.59%) |
| occurrences (all) | 19 | 12 | 9 |
| Loss of appetite | | | |
| alternative assessment type: Systematic | | | |
| subjects affected / exposed ^[7] | 14 / 92 (15.22%) | 10 / 82 (12.20%) | 9 / 85 (10.59%) |
| occurrences (all) | 14 | 10 | 9 |

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events was done only for subjects for whom results were available.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events was done only for subjects for whom results were available.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events was done only for subjects for whom results were available.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events was done only for subjects for whom results were available.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events was done only for subjects for whom results were available.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events was done only for subjects for whom results were available.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Analysis of adverse events was done only for subjects for whom results were available.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---------------|--|
| 16 April 2010 | The inclusion criteria for enrolment in the Pn-Pn (booster dose) groups has been modified to 9-18 months of age at the time of randomisation instead of 9-12 months due to a delay in the study start. This amendment extended the age range at the time of randomization of subjects who were primed in the primary vaccination study 10PN-PD-DIT-037 and thereby optimized the number of primed subjects to be included in the booster dose groups in this study. This amendment also extended the age at the time of booster vaccination in the Pn-Pn9 Group (early booster group) to 9-18 months instead of 9-12 months in order to keep the study fully randomized; giving the opportunity to any primed subject to be randomly allocated to one of the two booster groups. For the purpose of analysis, this group was split to 9-12 months and 13-18 months in order to have an analysis on the early booster subset for the primary objective. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported